Trial reportInflammatory bowel diseases
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.
Trial report in Inflammatory bowel diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Histologic scoring indices for evaluation of disease activity in ulcerative colitis.The Cochrane database of systematic reviews · 2017Pooled it
- Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.Inflammatory bowel diseases · 2018Trial
- Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis.Digestive diseases and sciences · 2017Trial
- Design of CellProfiler-Based Pipelines Enabling the Attribution of Molecular Stress Markers to Specific Tissue and Subcellular Compartments of the Colonic Mucosa.Cellular and molecular gastroenterology and hepatology · 2026Article
- Oxidative Stress-Related Biomarkers in Inflammatory Bowel Disease: Dual Tools for Remission Assessment and Prediction of Treatment Outcome.Antioxidants (Basel, Switzerland) · 2025Article
- Article
- Preliminary exploration of mRNA, lncRNA, and miRNA expressions in the bovine jejunum unveils novel aspects of Mycobacterium avium subspecies paratuberculosis infections.BMC genomics · 2025Article
- A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UC.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- Serum Activin A Is a Novel Biomarker of Endoscopic Activity in Ulcerative Colitis.Gastroenterology research · 2023Article
- A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study.Endoscopy international open · 2023Article
- The albumin to globulin ratio is associated with clinical outcome in Japanese patients with ulcerative colitis.Annals of coloproctology · 2023Article
- Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.Inflammatory bowel diseases · 2023Article
- Review
- Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.Biomedicines · 2022Article
- Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis.Crohn's & colitis 360 · 2022Article
- Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?Intestinal research · 2022Article
- Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study.Frontiers in public health · 2022Article
- Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2022Article
- Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission.Gut and liver · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with ulcerative colitis (UC) who are in clinical remission may still have underlying endoscopic inflammation, which is associated with inferior clinical outcomes. The goal of this study was to determine the prevalence of active endoscopic disease, and factors associated with it, in patients with UC who are in clinical remission.
methodsProspective observational study in a single center. Patients with UC in clinical remission (by Simple Clinical Colitis Activity Index) were enrolled prospectively at the time of surveillance colonoscopy. Disease phenotype, endoscopic activity (Mayo subscore), and histologic score (Geboes) were recorded, and blood was drawn for peripheral blood biomarkers.
resultsOverall, 149 patients in clinical remission were prospectively enrolled in this cohort; 81% had been in clinical remission for >6 months, and 86% were currently prescribed maintenance medications. At endoscopy, 45% of patients in clinical remission had any endoscopic inflammation (Mayo endoscopy subscore >0), and 13% had scores >1. In a multivariate model, variables independently associated with a Mayo endoscopic score >1 were remission for <6 months (P = 0.001), white blood count (P = 0.01), and C-reactive protein level (P = 0.009). A model combining these 3 variables had a sensitivity of 94% and a specificity of 73% for predicting moderate-to-severe endoscopic activity in patients in clinical remission (area under the curve, 0.86). In an unselected subgroup of patients who had peripheral blood mononuclear cell messenger RNA profiling, GATA3 messenger RNA levels were significantly higher in patients with endoscopic activity.
conclusionsDuration of clinical remission, white blood count, and C-reactive protein level can predict the probability of ongoing endoscopic activity, despite clinical remission in patients with UC. These parameters could be used to identify patients who require intensification of treatment to achieve mucosal healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.